# Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction &gt; 40%

Study · id `cardio:ct-nct04986202` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04986202](<https://clinicaltrials.gov/study/NCT04986202>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04986202

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 711 participants.

## Technical summary

Registry record NCT04986202. Randomized; triple masking; primary purpose treatment. Start 2021-06-30 (actual); primary completion 2024-03-27 (actual). Results posted on 2025-08-27.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 711 participants (enrolled count; ClinicalTrials.gov record NCT04986202, source copy `cardio:ctgov-nct04986202-2025-08-27`, retrieved 2026-10-26)
- Started: 2021-06-30 (actual) (ClinicalTrials.gov record NCT04986202, source copy `cardio:ctgov-nct04986202-2025-08-27`, retrieved 2026-10-26)
- Primary completion: 2024-03-27 (actual) (ClinicalTrials.gov record NCT04986202, source copy `cardio:ctgov-nct04986202-2025-08-27`, retrieved 2026-10-26)
- Completion: 2024-03-27 (actual) (ClinicalTrials.gov record NCT04986202, source copy `cardio:ctgov-nct04986202-2025-08-27`, retrieved 2026-10-26)
- Results first posted: 2025-08-27 (ClinicalTrials.gov record NCT04986202, source copy `cardio:ctgov-nct04986202-2025-08-27`, retrieved 2026-10-26)
- Countries: United States; Australia; Belgium; Brazil; Bulgaria; Canada; Czechia; Denmark; France; Hungary; Japan; Netherlands; Poland; Russia; Slovakia; Sweden; Taiwan; Türkiye (ClinicalTrials.gov record NCT04986202, source copy `cardio:ctgov-nct04986202-2025-08-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04986202-2025-08-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction &gt; 40%
- Acronym: ENDEAVOR
- Condition: Heart Failure With Preserved Ejection Fraction
- Intervention (Drug): AZD4831
- Intervention (Other): Placebo
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition term reads as this condition, and the trial is coded with its broader condition: Heart failure with mildly reduced or preserved ejection fraction (`cardio:hfpef`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Myeloperoxidase inhibition with mitiperstat in heart failure with preserved or mildly reduced ejection fraction: a randomized phase 2b trial (`cardio:pubmed-42717033`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 4a38a4fadd8523280ec36fcf20a03550375f4912160953809c418e1f2b443f71
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
